Philogen S.p.A. (PHIL)の価格はいくらですか

Philogen S.p.A. (PHIL)の価格は$27.76です

Philogen S.p.A. (PHIL)の時価総額は何ですか

Philogen S.p.A. (PHIL)の時価総額は$801.60Mです

Philogen S.p.A.（PHIL）の株価履歴

Philogen S.p.A. is a biotechnology firm dedicated to creating therapeutic agents for cancer and persistent inflammatory conditions. Among its pipeline, Nidlegy is being developed as an intralesional therapy for localized melanoma and non-melanoma skin cancers, combining the immunocytokines L19IL2 and L19TNF. Another key product is Fibromun, a human immunomodulatory agent composed of the L19 antibody and TNF, aimed at treating soft tissue sarcoma, leiomyosarcoma, and glioma. Darleukin, also known as L19IL2, is a human immunostimulatory product that integrates the human L19 antibody with the human cytokine interleukin-2 (IL2); it is currently undergoing Phase II clinical trials for addressing non-small cell lung cancer. The company's developmental efforts also include Dodekin, a human immunostimulatory product in Phase I/II clinical trials, consisting of a vascular targeting antibody fused with interleukin-12, designed to combat advanced solid tumors. For chronic inflammation, Dekavil (F8IL10), an anti-inflammatory compound, is in Phase I clinical trials. Furthermore, Philogen is advancing diagnostic radiotracers: Onco IX (PHC-102), a 99mTc labelled small molecule, is in Phase I, intended for the non-invasive detection of solid tumors that express carbonic anhydrase IX (CAIX). Similarly, OncoFAP, another small molecule radiotracer, is also in Phase I, focusing on the non-invasive identification of various metastatic solid tumors by targeting fibroblast activation protein. Established in 1996, Philogen S.p.A. operates from its headquarters in Sovicille, Italy.

年	パフォーマンス
2026 (TTM)	-1.23%
2025	37.47%
2024	0.27%
2023	0.00%

年

パフォーマンス

2026 (TTM)

-1.23%

2025

37.47%

2024

0.27%

2023

0.00%

企業	株価	変化率 1年%	国
Vertex Pharmaceuticals Incorporated VRTX.US	$542.09	38.63%	US
Argenx SE ARGX.US	$1.03K	44.13%	NL
CSL Limited CSL.AX	$121.53	-12.70%	AU
Moderna, Inc. MRNA.US	$138.18	473.58%	US
Lonza Group AG LONN.SW	$759.27	7.20%	CH

企業

株価

変化率 1年%

国